Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Exon Recombination02:32

Exon Recombination

4.3K
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes. 
Exon shuffling follows “splice frame rules.” Each exon...
4.3K
Base Excision Repair01:54

Base Excision Repair

5.4K
5.4K
Base Excision Repair01:54

Base Excision Repair

27.3K
One of the common DNA damages is the chemical alteration of single bases by alkylation, oxidation, or deamination. The altered bases cause mispairing and strand breakage during replication. This type of damage causes minimal change to the DNA double helix structure and can be repaired by the base excision repair (BER) pathways. BER corrects damaged DNA sequences by removing the damaged base and restoring the original base sequence using the complementary strand as a template.
The first step of...
27.3K
Gene Therapy00:59

Gene Therapy

27.9K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.9K
Gene Therapy00:59

Gene Therapy

4.7K
4.7K
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

8.2K
Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
8.2K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Dynamic Reorganization of Developmental to Adult Genome Topology Controls the Initiation and Stabilization of the Human Muscle Stem Cell State.

bioRxiv : the preprint server for biology·2026
Same author

Transcytotic transportation of size-controlled nanocarriers into dystrophic skeletal muscle leads to therapeutic outcome in mice.

Nature communications·2025
Same author

Old World alphaviruses use distinct mechanisms to infect brain microvascular endothelial cells for neuroinvasion.

Cell reports·2025
Same author

Macrophage-derived Spp1 promotes intramuscular fat in dystrophic muscle.

JCI insight·2025
Same author

DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function.

Nature communications·2025
Same author

Old World alphaviruses use distinct mechanisms to infect brain microvascular endothelial cells for neuroinvasion.

bioRxiv : the preprint server for biology·2025

関連する実験動画

Updated: Mar 11, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K

エクソンスキップ療法

Courtney S Young1, April D Pyle2

  • 1Molecular Biology Interdepartmental Program, Center for Duchenne Muscular Dystrophy, Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research, University of California, Los Angeles, Los Angeles, CA 90095.

Cell
|November 19, 2016
PubMed
まとめ
この要約は機械生成です。

Exondys 51は,デュシェンヌ筋縮症 (DMD) の治療にFDAが承認した最初の治療法で,適格な患者の読み取りフレームを回復するために,エクソン51をターゲットにしています. この治療は,ダイストロフィン発現を有効性の代替マーカーとして利用します.

さらに関連する動画

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.4K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K

関連する実験動画

Last Updated: Mar 11, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

19.3K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

7.4K
Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
06:20

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells

Published on: May 7, 2020

7.5K

科学分野:

  • 生物化学
  • 遺伝学
  • 神経学

背景:

  • デュシェン筋縮症 (DMD) は進行性遺伝疾患である.
  • DMDの現在の治療法は限られており,新しい治療法が必要である.

研究 の 目的:

  • デュシェンヌ筋縮症の新たな治療法としてExondys 51 (エテプリルセン) を導入する.
  • Exondysの作用機構と規制当局の承認を強調する.

主な方法:

  • Exondys 51は反感覚オリゴヌクレオチドを用いて,ディストロフィン遺伝子のエクソン51を標的にし,スキップする.
  • このエクソンスキップは,読み取り枠を回復し,短縮されたディストロフィンタンパク質の生成を可能にします.

主要な成果:

  • Exondys 51は,ディストロフィン発現レベルに基づいて,FDAの加速承認を受けました.
  • この治療は,エクソン51スキップに敏感な変異を有するDMD患者で,約13%の症例で用いる.

結論:

  • Exondys 51は,デュシェンヌ筋縮症の治療における重要な進歩を表しています.
  • この承認は,希少疾患の標的遺伝療法の可能性を強調しています.